Sector Update: Healthcare – Video

Posted by Dr. Michael White, Published on November 2nd, 2012
()



Sector Update: Healthcare
Shares of healthcare companies are lower ahead of the bell with Johnson Johnson (JNJ) and AstraZeneca Plc (AZN) reportedly stopping studies of experimental painkillers over concerns the new class of drugs may raise the risk of joint damage, Bloomberg reports. Endo Pharmaceutical Holdings (ENDP) said US regulators have approved its Fortesta gel as a treatment for hypogonadism or low testosterone. The company expects to launch Fortesta in the US early next year. St. Jude Medical (STJ) said it secured a new, $1.5 billion credit agreement with a group of lenders led by Bank of America (BAC), replacing a $1 billion loan package established in December 2006 used for general corporate purposes and to support its commercial paper program. Borrowing under the new pact running through 2015 will bear interest at LIBOR plus 0.875%, subject to revision if there #39;s a change in St. Jude #39;s credit rating.From:FinancialNewsOnlineViews:228 3ratingsTime:01:07More inNews Politics

View original post here:

Sector Update: Healthcare - Video

Contact Us Now

Your Name (*)
Your Email (*)
Your Phone (*)
Select A Program
Select Your US State (*)
Select your age (30+ only)
Confirm over 30 years old (*) Yes
Confirm United States Resident? (*) Yes
(*) - Required

After completing the contact form above, press the submit button. We will send you a confirmation email. Please check your email. For security purposes, please give us a call at 1-800-469-3343 if you don't receive an email.


Related Post

How useful was this post?

Click on a smiley face to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Word Count: 167

Comments are closed.


effects of what the testosterone specialist low are side

testosterone enanthate powder
percent free testosterone levels
low t test